QNTM

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

QNTM
Closed
$3.25
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The firm is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The firm has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Country

CA

CEO

Mr. Zeeshan Saeed

IPO date

2018

Employees

10

ISIN

CA74764Y2050

Key stats

Open

$3.36

Volume

63.67K

Market cap

$28.47M

Prev. close

$3.41

Impl / hst vl

-

Open interest

$0.00

$3.23

Day’s Range

$3.48

$2.07

52W Range

$10.81

Valuation

33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
33.74
Current ratio
0.63
Debt / Equity
-
ROE
-625.19%
Gross margin
-
Income growth
348.05%
FCF growth
446.07

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$32.04
The top 3 analysts forecasts that 12-month price may increase by 885.95%, with a low of $31.73 and a high of $32.99
$31.73
Low
$32.04
Avg
$32.99
High
Current price

Earnings

Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$13.56M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply